Cargando…

Naringin prevents HIV-1 protease inhibitors-induced metabolic complications in vivo

BACKGROUND: Insulin resistance, glucose intolerance and overt diabetes are known metabolic complications associated with chronic use of HIV-Protease Inhibitors. Naringin is a grapefruit-derived flavonoid with anti-diabetic, anti-dyslipidemia, anti-inflammatory and anti-oxidant activities. OBJECTIVES...

Descripción completa

Detalles Bibliográficos
Autores principales: Nzuza, Sanelisiwe, Zondi, Sindiswa, Owira, Peter M. O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679664/
https://www.ncbi.nlm.nih.gov/pubmed/29121676
http://dx.doi.org/10.1371/journal.pone.0183355
_version_ 1783277625636028416
author Nzuza, Sanelisiwe
Zondi, Sindiswa
Owira, Peter M. O.
author_facet Nzuza, Sanelisiwe
Zondi, Sindiswa
Owira, Peter M. O.
author_sort Nzuza, Sanelisiwe
collection PubMed
description BACKGROUND: Insulin resistance, glucose intolerance and overt diabetes are known metabolic complications associated with chronic use of HIV-Protease Inhibitors. Naringin is a grapefruit-derived flavonoid with anti-diabetic, anti-dyslipidemia, anti-inflammatory and anti-oxidant activities. OBJECTIVES: The study investigated the protective effects of naringin on glucose intolerance and impaired insulin secretion and signaling in vivo. METHODS: Male Wistar rats were divided into six groups (n = 6) and were daily orally treated with distilled water {3.0 ml/kg body weight (BW)}, atazanavir (133 mg/kg BW), saquinavir (333 mg/kg BW) with or without naringin (50 mg/kg BW), respectively for 56 days. Body weights and water consumption were recorded daily. Glucose tolerance tests were carried out on day 55 of the treatment and thereafter, the rats were sacrificed by halothane overdose. RESULTS: Atazanavir (ATV)- or saquinavir (SQV)-treated rats exhibited significant weight loss, polydipsia, elevated Fasting blood glucose (FBG), reduced Fasting Plasma Insulin (FPI) and expression of phosphorylated, Insulin Receptor Substrate-1 (IRS-1) and Akt proteins, hepatic and pancreatic glucokinase levels, and also increasing pancreatic caspase-3 and -9 as well as UCP2 protein expressions compared to controls, respectively. These effects were completely reversed by naringin treatment. CONCLUSION: Naringin prevents PI-induced glucose intolerance and impairment of insulin signaling and as nutritional supplement it could therefore alleviate metabolic complications associated with antiretroviral therapy.
format Online
Article
Text
id pubmed-5679664
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-56796642017-11-18 Naringin prevents HIV-1 protease inhibitors-induced metabolic complications in vivo Nzuza, Sanelisiwe Zondi, Sindiswa Owira, Peter M. O. PLoS One Research Article BACKGROUND: Insulin resistance, glucose intolerance and overt diabetes are known metabolic complications associated with chronic use of HIV-Protease Inhibitors. Naringin is a grapefruit-derived flavonoid with anti-diabetic, anti-dyslipidemia, anti-inflammatory and anti-oxidant activities. OBJECTIVES: The study investigated the protective effects of naringin on glucose intolerance and impaired insulin secretion and signaling in vivo. METHODS: Male Wistar rats were divided into six groups (n = 6) and were daily orally treated with distilled water {3.0 ml/kg body weight (BW)}, atazanavir (133 mg/kg BW), saquinavir (333 mg/kg BW) with or without naringin (50 mg/kg BW), respectively for 56 days. Body weights and water consumption were recorded daily. Glucose tolerance tests were carried out on day 55 of the treatment and thereafter, the rats were sacrificed by halothane overdose. RESULTS: Atazanavir (ATV)- or saquinavir (SQV)-treated rats exhibited significant weight loss, polydipsia, elevated Fasting blood glucose (FBG), reduced Fasting Plasma Insulin (FPI) and expression of phosphorylated, Insulin Receptor Substrate-1 (IRS-1) and Akt proteins, hepatic and pancreatic glucokinase levels, and also increasing pancreatic caspase-3 and -9 as well as UCP2 protein expressions compared to controls, respectively. These effects were completely reversed by naringin treatment. CONCLUSION: Naringin prevents PI-induced glucose intolerance and impairment of insulin signaling and as nutritional supplement it could therefore alleviate metabolic complications associated with antiretroviral therapy. Public Library of Science 2017-11-09 /pmc/articles/PMC5679664/ /pubmed/29121676 http://dx.doi.org/10.1371/journal.pone.0183355 Text en © 2017 Nzuza et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Nzuza, Sanelisiwe
Zondi, Sindiswa
Owira, Peter M. O.
Naringin prevents HIV-1 protease inhibitors-induced metabolic complications in vivo
title Naringin prevents HIV-1 protease inhibitors-induced metabolic complications in vivo
title_full Naringin prevents HIV-1 protease inhibitors-induced metabolic complications in vivo
title_fullStr Naringin prevents HIV-1 protease inhibitors-induced metabolic complications in vivo
title_full_unstemmed Naringin prevents HIV-1 protease inhibitors-induced metabolic complications in vivo
title_short Naringin prevents HIV-1 protease inhibitors-induced metabolic complications in vivo
title_sort naringin prevents hiv-1 protease inhibitors-induced metabolic complications in vivo
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679664/
https://www.ncbi.nlm.nih.gov/pubmed/29121676
http://dx.doi.org/10.1371/journal.pone.0183355
work_keys_str_mv AT nzuzasanelisiwe naringinpreventshiv1proteaseinhibitorsinducedmetaboliccomplicationsinvivo
AT zondisindiswa naringinpreventshiv1proteaseinhibitorsinducedmetaboliccomplicationsinvivo
AT owirapetermo naringinpreventshiv1proteaseinhibitorsinducedmetaboliccomplicationsinvivo